Announced
Completed
Synopsis
ARCH Venture Capital, a venture capital firm, led a $50m Series A round in Vilya, a biotechnology company. Vilya’s computational design platform leverages advanced machine learning and other computational approaches to explore an exponentially larger chemical space and design desired drug properties. These capabilities position the company to precisely target disease biology.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.